Please enable Javascript
Peter Voorhees, MD
Peter Voorhees, MD, is from the Levine Cancer Institute.
Articles by Peter Voorhees, MD
Ongoing Debates in the Management of Smoldering Myeloma
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
July 8, 2025
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
View More
'The HemOnc Pulse Live': Controversies in Frontline Myeloma
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
July 3, 2025
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Listen Now
Navigating Relapsed Myeloma: Expert Panel Tackles Unanswered Questions
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
July 8, 2025
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
View More
Dr. Peter Voorhees on T-Cell Fitness and the Potential of Cilta-Cel in Earlier Lines of Therapy
Melissa Badamo
Myeloma
|
June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
View More
Dr. Peter Voorhees Shares ‘Impressive Results’ From CARTITUDE-1 Trial in Myeloma
Melissa Badamo
Myeloma
|
June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
View More
Panel Discusses Best Practices for Post-CAR-T Management with Local Health Care Teams
Thomas Martin, MD
Video Insights
|
May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
View More
Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection
Thomas Martin, MD
Video Insights
|
May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
View More
Bispecific Versus CAR T-Cell Therapy for Myeloma, Bridging Therapy Needs for CAR-T
Thomas Martin, MD
Video Insights
|
May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
View More
Who Is the Right Patient for CAR-T Therapy?
Thomas Martin, MD
Video Insights
|
May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
View More
Frontline CAR-T Use and the 'Sweet Spot' for Treatment Sequencing
Thomas Martin, MD
Video Insights
|
May 5, 2023
The panel addresses the potential for frontline CAR-T use.
View More
Moving CAR-T Therapy Earlier in the Myeloma Treatment Course
Thomas Martin, MD
Video Insights
|
May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
View More
Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
View More
Dual-Targeting, Allogeneic CARs Are Options to ‘Keep Myeloma on its Toes’
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
View More
A Look at the CAR-T Pipeline: ddBCMA and LUMMICAR
Thomas Martin, MD
Video Insights
|
May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
View More
Ciltacabtagene Autoleucel and CARTITUDE Findings in Relapsed/Refractory Myeloma
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
View More
Idecabtagene Vicleucel for Myeloma: KarMMa Study Results and Real-World Evidence
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
View More
Spotlight on BCMA: A Major Target for Multiple Myeloma
Thomas Martin, MD
Video Insights
|
May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
View More